If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 1 - 10 of 17
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer,
Colorectal,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Breast Cancers,
Brain and Spine Cancers,
Other Respiratory,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus
A Phase I, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of SPYK04 as Monotherapy in Patients with Locally Advanced or Metastatic Solid Tumors
A Phase 1 Study of Spyk04 as Monotherapy in Patients with Solid Tumors
Protocol No
CHUGAI-SPK101JG
Categories
Cancer,
Ovary,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gastrointestinal Cancers,
Breast Cancers,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus,
Colorectal,
Gynecologic Cancers
Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial
This study will evaluate the efficacy and safety of multiple therapies that are selected
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
using somatic alterations and potential predictive biomarkers identified via NGS assays
in patients with solid tumors.
Protocol No
HOFFMANN-BO41932-TAPISTRY
Categories
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRAS G12C Mutant Advanced Solid Tumors
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Eye/Orbital Cancers,
Endocrine Cancers,
Breast Cancers,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus
Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol No
NRG-GU012-SAMURAI
Categories
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases
Protocol No
NRG-BN012
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Breast Cancers,
Lung,
Esophagus,
Melanoma, Skin,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Uterine,
Ovary,
Cervix,
Stomach,
Pancreas/Liver,
Esophagus
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination with Nivolumab or Standard of Care in Patients with Locally Advanced or Metastatic Solid Tumors
This project is being done to find out the highest tolerable dose of TST001 that can be given to patients when given via IV once every 2 or 3 weeks, what are the side effects, how much TST001 is in the blood at a specific times after dosing and how does the body get rid of it.
Protocol No
MABSPACE-TST001-1001
Categories
Cancer,
Cervix,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Eye/Orbital Cancers,
Endocrine Cancers,
Breast Cancers,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary
Phase III Trial of Salvage Stereotactic Radiosurgery (SRS) or SRS + Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for First or Second Distant Brain Relapse After Upfront SRS with Brain Metastasis Velocity >/= 4 Brain Metastases/Year
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
Protocol No
NRG-BN009
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Breast Cancers,
Lung,
Esophagus,
Melanoma, Skin,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Uterine,
Ovary,
Cervix,
Stomach,
Pancreas/Liver,
Esophagus
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
To assess the safety, tolerability, dose-limiting toxicities (DLTs), and determine the maximum tolerated dose of INBRX-106 as a single agent administered as an intravenous infusion and in combination with pembrolizumab.
Protocol No
INHIBRX-PH1-INBRX-106
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
A Phase 1/2 Trial of MRTX1719 in Patients with Advanced Solid Tumors with Homozygous MTAP Deletion
Protocol No
MIRATI-1719-001
Categories
Cancer,
Colorectal,
Early Phase/Multiple Disease Site Cancers,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Breast Cancers,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus